13.05.2022 - POINT s manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled. CTA filed with Health Canada for Phase 1 therapeutic trial for PNT6555, the .
Harnessing the Power of Uranium to Treat Disease newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.
Viewpoint Molecular Targeting, Inc.: Viewpoint Molecular Targeting Enters into Long-Term Supply Agreement with the National Isotope Development Center of the U.S. Department of Energy Isotope Program
??
-GEN isotope generator, which enables a nimble supply of therapeutic radioisotopes with the power of alpha-particle therapy for cancer
CORALVILLE, IA / ACCESSWIRE / February 18, 2021
/ Viewpoint Molecular Targeting, Inc. ( Viewpoint or the Company ), a radiopharmaceutical company developing precision α-particle oncology
therapeutics and complementary diagnostic imaging agents, today announced it has entered into an agreement with the National Isotope Development Center (NIDC) for the long-term supply of parent feedstock radionuclide Th-228 for the manufacturing of the Company s Ra-224/Pb-212 generator, VMT-??-GEN. The long-term agreement provides deliveries from 2021 through 2030.
Viewpoint Molecular Targeting(TM) Enters into Long-Term Supply Agreement with the National Isotope Development Center of the U S Department of Energy Isotope Program saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.